CoChat
Sign Up
Cited by 24

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Is the IL-10 Promoter Polymorphism at Position -592 Associated with Immune System-Related Diseases?

Karimabad, Mojgan Noroozi, Arababadi, Mohammad Kazemi, Hakimizadeh, Elham, Daredori, Hassan Yousefi, Nazari, Mahmood, Hassanshahi, Gholamhossein, Kennedy, Derek·2013·Inflammation
DOI 10.1007/s10753-012-9517-7
Open this paper in CoChat — free account

Abstract

Immune responses are the main causes of immune system-related diseases such as hypersensitivities and autoimmunity. It has also been established that cytokines play key roles in the regulation of immune responses which have been shown to be important in the pathogenesis of the diseases. IL-10, the main anti-inflammatory cytokine, is produced by several immune cells such as T regulatory and Th2 lymphocytes, activated macrophages, B regulatory lymphocytes as well as other cell types. It plays a key role in the regulation of immune responses after microbe elimination (homeostasis) and against self-antigens to prevent hypersensitivity and autoimmune diseases, respectively. Studies showed that a single nucleotide polymorphism (SNP) at the -592 position of IL-10 is associated with its regulation of expression. This review addresses the recent information regarding the association of the polymorphism at position -592 of IL-10 with immune-related diseases including type 2 diabetes with and without nephropathy, multiple sclerosis, and asthma with an emphasize on Iranian patients.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10753-012-9517-7

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 60

  1. Chiang, Y.J., H.K. Kole, K. Brown, et al. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403: 216–220. · DOI
  2. Arababadi, M.K., B.N. Ahmadabadi, and D. Kennedy. 2012. Current information on the immunological status of occult hepatitis B infection. Transfusion. doi: 10.1111/j.1537-2995.2012.03575.x . · DOI
  3. van Eden, W., A. Koets, P. van Kooten, et al. 2003. Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine 21: 897–901. · DOI
  4. Miyara, M., K. Wing, and S. Sakaguchi. 2009. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. The Journal of Allergy and Clinical Immunology 123: 749–755. quiz 756–747. · DOI
  5. Li, Y.P., V. Latger-Canard, L. Marchal, et al. 2006. The regulatory role of dendritic cells in the immune tolerance. Biomedical Materials and Engineering 16: S163–S170.
  6. Karjalainen, J., J. Hulkkonen, M.M. Nieminen, et al. 2003. Interleukin-10 gene promoter region polymorphism is associated with eosinophil count and circulating immunoglobulin E in adult asthma. Clinical and Experimental Allergy 33: 78–83. · DOI
  7. Arababadi, M.K., R. Mosavi, H. Khorramdelazad, et al. 2010. Cytokine patterns after therapy with Avonex(R), Rebif(R), Betaferon(R) and CinnoVex in relapsing-remitting multiple sclerosis in Iranian patients. Biomarkers in Medicine 4: 755–759. · DOI
  8. Arababadi, M.K., G. Hassanshahi, H. Azin, et al. 2010. No association between CCR5 ≏ 32 mutation and multiple sclerosis in patients of south-eastern of Iran. Laboratory Medicine 41: 31–33. · DOI
  9. Arababadi, M.K., R. Mosavi, H. Teimori, et al. 2011. Association of IL-4 polymorphisms with multiple sclerosis in south-eastern Iranian patients. Annals of Saudi Medicine 32(2): 127–130. · DOI
  10. Arababadi, M.K., H. Abousaidi, G. Hassanshahi, et al. 2011. Association of exon 9 but not intron 8 VDR polymorphisms with asthma in south-eastern Iranian patients. Iranian Journal of Basic Medical Science 14: 107–115.
  11. Cookson, W. 1999. The alliance of genes and environment in asthma and allergy. Nature 402: B5–B11. · DOI
  12. Orihara, K., N. Dil, V. Anaparti, et al. 2011. What’s new in asthma pathophysiology and immunopathology? Expert Review of Respiratory Medicine 4: 605–629. · DOI
  13. Yaghini, N., M. Mahmoodi, G. Asadikaram, et al. 2011. Genetic variation of IL-12B (+1188 region) is associated with its decreased circulating levels and susceptibility to type 2 diabetes: a study on south-eastern Iranian diabetic patients. Biomarkers in Medicine 6(1): 89–95. · DOI
  14. Cruz, M., C. Maldonado-Bernal, R. Mondragon-Gonzalez, et al. 2008. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. Journal of Endocrinological Investigation 31: 694–699. · DOI
  15. Yaghini, N., M. Mahmoodi, G. Asadikaram, et al. 2011. Serum levels of Interleukin 10 (IL-10) in patients with type 2 diabetes. Iranian Red Crescent Medical Journal 13(10): 752.
  16. Arababadi, M.K., R. Nosratabadi, G. Hassanshahi, et al. 2009. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases? Diabetes Research and Clinical Practice 87: 33–37. · DOI
  17. Arababadi, M.K., A.A. Pourfathollah, S. Daneshmandi, et al. 2009. Evaluation of relation between IL-4 and IFN-g polymorphisms and type 2 diabetes. Iranian Journal of Basic Medical Science 12: 100–104.
  18. Arababadi, M.K., N. Naghavi, G. Hassanshahi, et al. 2009. Is CCR5-Delta32 mutation associated with diabetic nephropathy in type 2 diabetes? Annals of Saudi Medicine 29: 413. · DOI
  19. Groux, H., and F. Cottrez. 2003. The complex role of interleukin-10 in autoimmunity. Journal of Autoimmunity 20: 281–285. · DOI
  20. Howell, W.M., and M.J. Rose-Zerilli. 2006. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Familial Cancer 5: 143–149. · DOI
  21. Sabat, R., G. Grutz, K. Warszawska, et al. 2010. Biology of interleukin-10. Cytokine & Growth Factor Reviews 21: 331–344. · DOI · Paper page
  22. Moore, K.W., R. de Waal Malefyt, R.L. Coffman, et al. 2001. Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology 19: 683–765. · DOI · Paper page
  23. Booy, R., S. Nadel, M. Hibberd, et al. 1997. Genetic influence on cytokine production in meningococcal disease. Lancet 349: 1176. · DOI
  24. Zhang, Y., J. Zhang, C. Tian, et al. 2011. The -1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer’s disease: a meta-analysis. Journal of Neurological Sciences 303: 133–138. · DOI
  25. Lopez, P., C. Gutierrez, and A. Suarez. 2010. IL-10 and TNFalpha genotypes in SLE. Journal of Biomedicine and Biotechnology 2010: 838390. · DOI
  26. Scapini, P., C. Lamagna, Y. Hu, et al. 2011. B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2011: 12.
  27. Arababadi, M.K. 2010. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iranian Journal of Kidney Diseases 4: 302–306.
  28. Nosratabadi, R., M.K. Arababadi, V.A. Salehabad, et al. 2010. Polymorphisms within exon 9 but not intron 8 of the vitamin D receptor are associated with the nephropathic complication of type-2 diabetes. International Journal of Immunogenetics 37: 1–5. · DOI
  29. Arababadi, M.K., M. Mirzaei, S.M.A. Sajadi, et al. 2011. Interleukin (IL)-10 gene polymorphisms is associated with type 2 diabetes with and without nephropathy: a study of patients from the South-East region of Iran. Inflammation 35(3): 797–802. · DOI
  30. Chang, J.H., H.R. Cha, D.S. Lee, et al. 1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One 5: e12925. · DOI
  31. Mtiraoui, N., I. Ezzidi, M. Kacem, et al. 2009. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients. Diabetes/Metabolism Research and Reviews 25: 57–63. · DOI
  32. Kung, W.J., C.C. Lin, S.H. Liu, et al. 2011. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technology & Therapeutics 12: 809–813. · DOI
  33. Ezzidi, I., N. Mtiraoui, M. Kacem, et al. 2009. Interleukin-10-592C/A, -819C/T and -1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes (T2DM) patients. Clinical Endocrinology 70: 401–407. · DOI
  34. Ishii, M., G. Hasegawa, M. Fukui, et al. 2005. Clinical and genetic characteristics of diabetic patients with high-titer (>10,000 U/ml) of antibodies to glutamic acid decarboxylase. Immunology Letters 99: 180–185. · DOI
  35. Scarpelli, D., M. Cardellini, F. Andreozzi, et al. 2006. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes 55: 1529–1533. · DOI
  36. Ascherio, A., K.L. Munger, K.C. Simon. Vitamin D and multiple sclerosis. Lancet Neurology 9: 599–612. · DOI
  37. Teunissen, C.E., J. Killestein, and G. Giovannoni. 2007. Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. Biomarkers in Medicine 1: 111–119. · DOI
  38. Glass, C.K., K. Saijo, B. Winner, et al. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918–934. · DOI · Paper page
  39. Nosratabadi, R., B.N. Ahmadabadi, M.K. Arababadi, et al. 2011. Association of polymorphism in the -592 region of IL-10 with multiple sclerosis in south-eastern Iranian patients. Iranian Red Crescent Medical Journal 32(2): 127–130.
  40. Almeras, L., B. Meresse, J. Seze, et al. 2002. Interleukin-10 promoter polymorphism in multiple sclerosis: association with disease progression. European Cytokine Network 13: 200–206.
  41. Forte, G.I., P. Ragonese, G. Salemi, et al. 2006. Search for genetic factors associated with susceptibility to multiple sclerosis. Annals of the New York Academy of Sciences 1067: 264–269. · DOI
  42. Luomala, M., T. Lehtimaki, H. Huhtala, et al. 2003. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurologica Scandinavica 108: 396–400. · DOI
  43. Mihailova, S., M. Ivanova, A. Mihaylova, et al. 2005. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. Journal of Neuroimmunology 168: 138–143. · DOI
  44. Wergeland, S., A. Beiske, H. Nyland, et al. 2005. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. European Journal of Neurology 12: 171–175. · DOI
  45. Azarpira, N., A. Borhani Haghighi, M. Pourjafar, et al. 2010. Interleukin 10 gene polymorphism in Iranian patients with multiple sclerosis. Acta Neurologica Taiwanica 19: 107–111.
  46. Pickard, C., C. Mann, P. Sinnott, et al. 1999. Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis. Journal of Neuroimmunology 101: 207–210. · DOI
  47. Sandford, A.J., S. Zhu, T.R. Bai, et al. 2001. The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. The Journal of Allergy and Clinical Immunology 108: 69–73. · DOI
  48. Zietkowski, Z., M.M. Tomasiak, R. Skiepko, et al. 2008. RANTES in exhaled breath condensate of stable and unstable asthma patients. Respiratory Medicine 102: 1198–1202. · DOI
  49. Abousaidi, H., R. Vazirinejad, M.K. Arababadi, et al. 2011. Lack of association between chemokine receptor 5 (CCR5) C32 mutation and pathogenesis of asthma: a study on Iranian asthma patients. Southern Medical Journal 104: 422–425. · DOI
  50. Pukelsheim, K., T. Stoeger, D. Kutschke, et al. 2010. Cytokine profiles in asthma families depend on age and phenotype. PLoS One 5: e14299. · DOI
  51. Zhang, J., H. Chen, L. Hu, et al. 2002. Correlation between polymorphism of IL-4 and IL-10 gene promoter and childhood asthma and their impact upon cytokine expression. Zhonghua Yi Xue Za Zhi 82: 114–118.
  52. Movahedi, M., S.A. Mahdaviani, N. Rezaei, et al. 2008. IL-10, TGF-beta, IL-2, IL-12, and IFN-gamma cytokine gene polymorphisms in asthma. The Journal of Asthma 45: 790–794. · DOI
  53. Hobbs, K., J. Negri, M. Klinnert, et al. 1998. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. American Journal of Respiratory and Critical Care Medicine 158: 1958–1962. · DOI
  54. Immervoll, T., S. Loesgen, G. Dutsch, et al. 2001. Fine mapping and single nucleotide polymorphism association results of candidate genes for asthma and related phenotypes. Human Mutation 18: 327–336. · DOI
  55. Kim, S.H., E.M. Yang, H.N. Lee, et al. 2009. Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. Allergy 64: 1221–1225. · DOI
  56. Trajkov, D., J. Mirkovska-Stojkovikj, T. Arsov, et al. 2008. Association of cytokine gene polymorphisms with bronchial asthma in Macedonians. Iranian Journal of Allergy, Asthma, and Immunology 7: 143–156.
  57. Zedan, M., A. Settin, M.K. Farag, et al. 2008. Gene polymorphisms of tumor necrosis factor alpha-308 and interleukin-10-1082 among asthmatic Egyptian children. Allergy and Asthma Proceedings 29: 268–273. · DOI
  58. Chatterjee, R., J. Batra, A. Kumar, et al. 2005. Interleukin-10 promoter polymorphisms and atopic asthma in North Indians. Clinical and Experimental Allergy 35: 914–919. · DOI
  59. Kazemi Arababadi, M., M. Reza Mirzaei, S.M. Ali Sajadi, et al. Interleukin (IL)-10 gene polymorphisms are associated with type 2 diabetes with and without nephropathy: a study of patients from the southeast region of Iran. Inflammation 35: 797–802. · DOI
  60. Kung, W.J., C.C. Lin, S.H. Liu, et al. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technology & Therapeutics 12: 809–813. · DOI

Cited by

Sorted by citations

See all 24

Metadata

Authors
Karimabad, M. N., Arababadi, M. K., Hakimizadeh, E., Daredori, H. Y., Nazari, M., Hassanshahi, G., & Kennedy, D.
Venue
Inflammation
Publisher
Springer Science and Business Media LLC
Published
2012-08-11
Volume
36
Issue
1
Pages
35-41
ISSN
  • 0360-3997
  • 1573-2576
DOI
10.1007/s10753-012-9517-7
Cited by
24
References
2
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review